XNAS · Healthcare · Medical - Pharmaceuticals
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.98 | -0.76 | +22.45% | $306.0M | ✅ Beat | -0.08% | +10.11% | — |
| 2026-02-19 | Q4 2025 | -1.13 | -1.54 | -36.28% | $263.8M | ❌ Miss | -0.99% | -6.83% | -15.53% |
| 2025-10-30 |
| Q3 2025 |
| -1.35 |
| -1.75 |
| -29.63% |
| $142.3M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | -1.31 | -1.70 | -29.77% | $107.4M | ❌ Miss | -1.94% | +16.88% | +32.75% |
| 2025-02-20 | Q4 2024 | -1.16 | -1.32 | -13.79% | $104.4M | ❌ Miss | -3.05% | -5.45% | -5.06% |
| 2024-10-31 | Q3 2024 | -1.22 | -1.27 | -4.10% | $93.4M | ❌ Miss | +1.55% | +6.55% | +7.64% |
| 2024-08-08 | Q2 2024 | -1.27 | -1.94 | -52.76% | $90.3M | ❌ Miss | +3.02% | +3.24% | +0.01% |
| 2024-05-09 | Q1 2024 | -1.23 | -1.06 | +13.82% | $75.5M | ✅ Beat | -1.55% | -4.85% | +127.07% |
Showing last 8 quarters.